Finance

Roʻyxatlar
600535:SHA
Tasly Pharmaceutical Group Co Ltd
14,04 CN¥
-0,35%
(-0,050) 1K
16-okt, 15:00:00 (GMT+8)  ·   CNY
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
600535 tikeri uchun statistika yaratilmoqda...
Ochish
14,18 CN¥
Yuqori
14,35 CN¥
Past
13,92 CN¥
Bozor kapitali
20,87 mlrd
Oʻrtacha hajm
11,45 mln
Hajmi
15,72 mln
Dividend
2,42%
Choraklik dividendlar
0,09 CN¥
Eks-dividend sanasi
29-may, 2026
P/E koeffitsiyenti
17,15
52 haftalik eng yuqori
16,24 CN¥
52 haftalik eng past
12,90 CN¥
Aksiya boʻyicha daromad
0,82 CN¥
Muomaladagi aksiyalar
1,51 mlrd
Xodimlar soni
11 ming
Ochish
14,18 CN¥
Yuqori
14,35 CN¥
Past
13,92 CN¥
Bozor kapitali
20,87 mlrd
Oʻrtacha hajm
11,45 mln
Hajmi
15,72 mln
Dividend
2,42%
Choraklik dividendlar
0,09 CN¥
Eks-dividend sanasi
29-may, 2026
P/E koeffitsiyenti
17,15
52 haftalik eng yuqori
16,24 CN¥
52 haftalik eng past
12,90 CN¥
Aksiya boʻyicha daromad
0,82 CN¥
Muomaladagi aksiyalar
1,51 mlrd
Xodimlar soni
11 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Tasly is a Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange. In 2009, Chinese pharmacologist Li Lianda claimed that a key product made by Tasly was unsafe. Tasly sued Li in 2013, alleging that Li's claim was baseless and was motivated by his financial and employment relations with Guangzhou Pharmaceutical, a direct competitor of Tasly. In September 2014, the Tianjin High People's Court ruled in favour of Tasly and ordered Li to issue an apology and pay Tasly 300,000 yuan in compensation. In February 2017, Tasly announced plans to form a joint venture with American multi-level marketing company Herbalife. Wikipedia
Tasly Pharmaceutical Group Co Ltd haqida
CEO-
Xodimlar soni10,6 ming
Asos solingan1994
Bosh ofislar-
Sektor-
Veb-sayttasly.com
Avvalgi hisobotlarBarcha qiymatlar – CNY
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – CNY
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
2,02 mlrd
1,93 mlrd
2,16 mlrd
2,04 mlrd
Sotilgan mahsulotning tannarxi
684,07 mln
659,71 mln
623,69 mln
654,28 mln
Daromad narxi
684,07 mln
659,71 mln
623,69 mln
654,28 mln
Tadqiqot va ishlanmalarga xarajatlar
210,48 mln
132,23 mln
191,62 mln
102,48 mln
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
844,05 mln
787,37 mln
874,15 mln
656,33 mln
Operatsion xarajatlar
1,06 mlrd
979,15 mln
1,08 mlrd
801,23 mln
Jami operatsion xarajatlar
1,74 mlrd
1,64 mlrd
1,70 mlrd
1,46 mlrd
Operatsion daromad
281,20 mln
286,94 mln
462,71 mln
580,75 mln
Boshqa nooperatsion daromad
-7,57 mln
-6,11 mln
-733,75 ming
-232,24 ming
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
248,13 mln
192,46 mln
461,52 mln
584,82 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
280,97 mln
289,16 mln
472,69 mln
588,33 mln
Daromad soligʻi boʻyicha xarajat
45,36 mln
123,68 mln
96,97 mln
64,84 mln
Amaldagi soliq stavkasi
18,28%
64,26%
21,01%
11,09%
Boshqa operatsion xarajatlar
1,56 mln
53,20 mln
17,23 mln
42,82 mln
Sof foyda
209,68 mln
120,59 mln
370,24 mln
522,44 mln
Sof foyda marjasi
10,37%
6,26%
17,10%
25,66%
Har bir aksiya foydasi
-
-
-
-
Foizlar va investitsiyalardan olingan daromadlar
14,77 mln
14,84 mln
14,04 mln
11,58 mln
Foizlarni toʻlash xarajatlari
-7,28 mln
-5,44 mln
-3,33 mln
-5,30 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
7,49 mln
9,39 mln
10,71 mln
6,29 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
380,28 mln
380,23 mln
555,99 mln
663,57 mln
Aktivlarni sotishdan olingan foyda yoki zarar
5,21 mln
-8,61 mln
-
-409,04 ming
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari